New Delhi: The government on Wednesday constituted a four-member committee of experts to examine the details and adverse event reports received from the World Health Organization (WHO) on the possible deaths of 66 children in The Gambia from four cough syrups manufactured in India. did. Official sources gave this information here.
He said that after examining and analyzing the adverse event report, causal link and all relevant details shared or likely to be shared by the World Health Organisation, the committee would advise the Drug Controller General of India (DCGI) on the further course of action and recommend Will do The development comes after the Haryana government ordered a halt to drug manufacturing at Maiden Pharmaceuticals’ Sonepat unit and sought clarification or suspension or cancellation of licenses within a week on “multiple violations” detected during a recent inspection. asked to face.
The suspension order comes days after the World Health Organization (WHO) cited the company-made cough syrup as a possible cause of death of 66 children in the African country of Gambia. The four-member committee of technical experts included Dr. YK Gupta, Vice-Chairman of the National Committee on Medicine, Dr. Pragya D. Yadav of the National Institute of Virology, Pune, Dr. Epidemiology Department of National Center for Disease Control (NCDC), New Delhi. Aarti Behl and A.K. of CDSCO Principal included.
According to official sources, WHO had informed the Central Bureau of Drugs Standard Control (CDSCO) on 29 September that they were providing technical assistance and advice to The Gambia. It is feared that children died after using drugs named Promethazine Oral Solution, Cofaxmalin Baby Cough Syrup, Mekoff Baby Cough Syrup, and Magrip N Cold Syrup. The manufacturing company of these drugs is Medan Pharmaceuticals Limited based in Haryana which exported them.
